September 9, 2015—Krista Pedley, the U.S. Public Health Service Commissioned Officer in charge of the 340B drug discount program, has been promoted from Commander to Captain. … [Read more...]
340B Mega-Guidance Would Limit Access to Drug Discounts
Groups worry program's costs may outweigh benefits for some providersSeptember 2, 2015—Healthcare providers would have less leeway to use 340B-discounted drugs under draft program guidelines released late last week. … [Read more...]
Breaking News: HRSA Releases 340B Omnibus Guidance
Comments will be due on or before Oct. 27August 27, 2015—The Health Resources and Services Administration released its 340B program omnibus guidance this morning. … [Read more...]
Americans Fed Up With High Drug Prices
The chorus has been growing for months and now it’s official: Americans across the political spectrum agree that prescription prices are too high. The drug industry could hardly have done a better job uniting the country. A new poll from the Kaiser Family Foundation finds that 72 percent of Americans believe drug costs are “unreasonable.” And in a sign of real trouble for the … [Read more...]
Healthcare Providers Comment on 340B Program Proposed Rule
Regulation addresses ceiling price calculation and drugmaker finesAugust 21, 2015—The Health Resources and Services Administration should clarify in a forthcoming 340B program rule that drugmakers must give refunds for all overcharges on 340B drugs above a reasonable dollar amount and within a reasonable amount of time after their discovery, including those due to routine average manufacturer price "true-ups," groups representing healthcare … [Read more...]
OMB Approves 340B Omnibus Guidelines
Milepost passed on the route to publicationAugust 19, 2015—The White House Office of Management and Budget has finished reviewing the proposed 340B program omnibus guidelines, moving them closer to publication for notice and comment in the Federal Register. … [Read more...]
CMS Submits Medicaid Drug Pricing Final Rule to OMB for Review
Last stop before publication for the long-delayed regulation?August 6, 2015—Three and a half years after being released for public comment, the Medicaid covered outpatient drug rule, a.k.a. the AMP (average manufacturer price) final rule, could finally be nearing the finish line. … [Read more...]